Back to Search
Start Over
Challenges faced when identifying patients for combination immunotherapy
- Source :
- Future Oncology. 13:1607-1618
- Publication Year :
- 2017
- Publisher :
- Future Medicine Ltd, 2017.
-
Abstract
- In 1996, Jim Allison demonstrated that blocking the immune regulatory molecule CTLA-4 with anit-CTLA4 antibody led to enhance tumor responses in mice. It would take an additional 15 years for human studies to confirm the potency and clinical efficacy of anti-CTLA4, ultimately leading to US FDA approval of the first checkpoint inhibitor, ipilimumab. Now with a plethora of immune-modulating agents demonstrating single agent safety and benefit across many tumor types, investigation on the optimal combination of immune-based therapies has begun in earnest. While there are many challenges, a central one is how to select which combination for which patient is the best. Here we review the current approaches that a practitioner can use to achieve this therapeutic goal.
- Subjects :
- 0301 basic medicine
Cancer Research
medicine.medical_specialty
medicine.medical_treatment
Immune checkpoint inhibitors
chemical and pharmacologic phenomena
Ipilimumab
Immunomodulation
Avelumab
03 medical and health sciences
Antineoplastic Agents, Immunological
0302 clinical medicine
Atezolizumab
Neoplasms
Antineoplastic Combined Chemotherapy Protocols
Biomarkers, Tumor
Animals
Humans
Medicine
Molecular Targeted Therapy
Clinical efficacy
Combination immunotherapy
Intensive care medicine
business.industry
General Medicine
Immunotherapy
Combined Modality Therapy
030104 developmental biology
Oncology
030220 oncology & carcinogenesis
Immunology
Nivolumab
business
Signal Transduction
medicine.drug
Subjects
Details
- ISSN :
- 17448301 and 14796694
- Volume :
- 13
- Database :
- OpenAIRE
- Journal :
- Future Oncology
- Accession number :
- edsair.doi.dedup.....77cde4cd3639d052670f86c62c21a6b6